Sign inCreate account

Report workspace tools

NCT07358546RECRUITINGanonymous

A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Efimosfermin Alfa in Adults With Varying Degrees of Hepatic Impairment Due to Steatotic Liver Disease

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

Efimosfermin alfa

Indication / condition

AI-normalized

Non-alcoholic Fatty Liver Disease

Intervention

Source record

Efimosfermin alfa

Source & freshness

Source record

NCT ID

NCT07358546

Original source

ClinicalTrials.gov

Source last updated

Apr 13, 2026

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07358546

Title

A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Efimosfermin Alfa in Adults With Varying Degrees of Hepatic Impairment Due to Steatotic Liver Disease

Sponsor

GlaxoSmithKline

Status

RECRUITING

Phase

PHASE1

Condition raw

Non-alcoholic Fatty Liver Disease

Condition normalized

Non-alcoholic Fatty Liver Disease

Modality raw

MASH

Modality normalized

small molecule

Target raw

Efimosfermin alfa

Target normalized

Efimosfermin alfa

Interventions

Efimosfermin alfa

Public preview

Source record

A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Efimosfermin Alfa in Adults With Varying Degrees of Hepatic Impairment Due to Steatotic Liver Disease is a PHASE1 clinical asset sponsored by GlaxoSmithKline in Non-alcoholic Fatty Liver Disease. SEO and diligence focus: Efimosfermin alfa, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Efimosfermin Alfa in Adults With Varying Degrees of Hepatic Impairment Due to Steatotic Liver Disease

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07358546

Status

RECRUITING

Phase

PHASE1

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Efimosfermin Alfa in Adults With Varying Degrees of Hepatic Impairment Due to Steatotic Liver Disease is a PHASE1 clinical asset sponsored by GlaxoSmithKline in Non-alcoholic Fatty Liver Disease. SEO and diligence focus: Efimosfermin alfa, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedApr 13, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07358546

Indication

Non-alcoholic Fatty Liver Disease

Modality

small molecule

Target

Efimosfermin alfa

Intervention

Efimosfermin alfa

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.